Amarantus
Enters into Exclusive Option Agreement with
Leipzig University to License IP Covering
Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid
PET
New York, NY USA
May 4,
2018 -- InvestorsHub NewsWire --
Amarantus
Bioscience Holdings, Inc. (OTC Pink:
AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus
biotechnology holding company, developing first-in-class orphan
neurologic, regenerative medicine and ophthalmic therapies
and
diagnostics
through its
subsidiaries, today announced
that it has entered
into an exclusive option agreement with Leipzig
University.
The
exclusive option agreement allows the
Company to
license rights to "LymPro Test 2.0" which incorporates
LymPro Test
results
with
those of
amyloid PET
imaging for
the diagnosis of Alzheimer's disease.
Under the terms of the
agreement, Amarantus acquired an exclusive option to evaluate
data produced from a German-based
clinical
study (LymPro PET 1)
initiated in
2016 and completed in 2017 under the
supervision of Dr. Thomas Arendt, the inventor of LymPro
Test.
Amarantus received
a summary of the data on May 2, 2018. Upon exercising the Company's exclusive
option, Amarantus and Leipzig will complete
negotiations to license LymPro IP and data created from LymPro PET 1
to
Amarantus, and collaborate on
a
confirmatory
20 subject trial (LymPro PET 2)
currently enrolling
under Dr. Arendt's supervision.
AAIC 2015
Poster Presentation of LymPro Test LP-002 Clinical Data
Amarantus
Alzheimer's Diagnostics Scientific Advisory Board
Dr. Ropacki
Appointed Chief Medical Advisor for Alzheimer's Blood Diagnostic
LymPro Test
About Alzheimer's
Disease
According to the Alzheimer's
Association, it is estimated that over 5.4 million people in the
United States suffer from Alzheimer's disease. Over 500,000
patients are diagnosed annually, with nearly one-in-eight older
Americans affected by the disease. Alzheimer's disease is the third
leading cause of death in the United States. The cost of unpaid
care in the United States is estimated at over $210 billion
annually. Total payments for care are estimated at over $200
billion annually, including $140 billion in cost to Medicare and
Medicaid. Alzheimer's expenditures in the United States are
expected to exceed $1.2 trillion by 2050. There is no cure or
effective treatment for Alzheimer's disease. Worldwide, about 35.6
million individuals have the disease and, according to the World
Health Organization, the number will double every 20 years to 115.4
million people with Alzheimer's by 2050.
About Dr. Arendt's research
at Leipzig University
Dr. Th. Arendt is Professor of
Neuroscience at Leipzig University where he runs the Paul
Flechsig
Institute of Brain
Research. He has a 30-year record in R&D of
therapeutic and diagnostic strategies of neurodegenerative
disorders
and made several seminal contributions to therapeutic concepts of
Alzheimers disease, including stem cell therapy and modulating
tumor suppressor genes. In the early 1980's, he was involved in
identifying the degeneration of the cholinergic system in
Alzheimers disease laying the basis for today's only available treatment. He
is one of the pioneers of the "cell-cycle theory" of
Alzheimers disease, which
he developed
towards a diagnostic and therapeutic concept.
About LymPro
Test
The Lymphocyte Proliferation
Test (LymPro Test) is a diagnostic blood test that determines the
ability of peripheral blood lymphocytes (PBLs) and monocytes to
withstand an exogenous mitogenic stimulation that induces them to
enter the cell cycle. It is believed that certain diseases, most
notably Alzheimer's disease, are the result of compromised cellular
machinery that leads to aberrant cell cycle re-entry by neurons
which then leads to apoptosis. LymPro is unique in the use of
peripheral blood lymphocytes as a surrogate for neuronal cell
function, suggesting a common relationship between PBLs and neurons
in the brain.
About Amarantus Bioscience
Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS) is a JLABS alumnus
biotechnology company developing treatments and
diagnostics for diseases in the areas of
neurology,
regenerative medicine and orphan diseases through its subsidiaries.
AMBS' wholly-owned subsidiary Elto Pharma,
Inc. has
development rights to eltoprazine, a Phase 2b-ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia,
Alzheimer's aggression and adult attention deficit hyperactivity
disorder, commonly known as ADHD. AMBS acquired the rights to the
Engineered Skin Substitute program, a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen
Corporation.
AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key
intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics,
Inc. is
developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine
PhenoGuard. The Company also re-acquired
rights to the Alzheimer's blood diagnostic
LymPro Test , MSPrecise and NuroPro.
For further
information please visit www.Amarantus.com, or connect with the Amarantus
on Facebook,LinkedIn,Twitterand Google+.
Amarantus
Investor and Media Contact:
Howard Gostfrand
American Capital Ventures,
Inc.
Office: 305-918-7000
Email: hg@amcapventures.com
Source: Amarantus Bioscience
Holdings, Inc.
